Navigation Links
Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
Date:9/9/2008

ORMD 0801 to be Tested on Type 2 Diabetic Volunteers

JERUSALEM, September 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today the signing of an agreement with ETI Karle Clinical Pvt. Ltd. (http://www.etiklinical.com), a clinical research organization (CRO) located in India, to conduct Phase 2B clinical trials on its oral insulin capsules.

The study is intended to evaluate the safety, tolerability and efficacy of ORMD 0801, Oramed's oral insulin capsule, on diabetic type 2 patients.

It is anticipated that the Phase 2B study will be conducted over several months starting in the first quarter of 2009, with approximately 60 subjects participating in the trial.

"Oramed has been able to demonstrate that ORMD 0801 has a good safety profile and effective on a small group of diabetes patients. This trial is intended to affirm that ORMD 0801 will perform to our expectation on a large group of type 2 diabetes patients," said Nadav Kidron, CEO of Oramed.

ETI Karle Clinical Pvt. Ltd is a Pan-Asian CRO, headquartered in Bangalore with a network of 60 clinical trial sites across all therapeutic areas, with access to 2 million patients, and 120 researchers.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001

Email: eric@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003

Email: matthew@oramed.com

ETI's Contacts:

Dr. M.V. Nagendran,

COO, ETI Karle Clinical Pvt. Ltd.

No. 72, Industrial Suburb,

Ward No. 10,

Near Ullas Theatre,

1st Block, Rajaji Nagar,

BANGALORE- 560 022, India

Cell: +91-9845010682

Office: +91-80-23371585

Email: nagendran@karlegroup.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
2. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
5. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
6. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
7. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
8. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... and Azusa, CA (PRWEB) , ... December 07, ... ... of distributed wastewater treatment and resource recovery solutions for industrial facilities, today announced ... , will be the first to use Cambrian’s novel water-energy purchase agreement (WEPA). ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... access program for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome ... and detection of hundreds of different genes. The selective early access program ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... for the fourth quarter and fiscal year ended September 30, 2016. ... , , ... -based life sciences and diagnostics company that develops and commercializes proprietary ... Highlights Achieved revenues of $1.4 million more than ...
(Date:12/6/2016)... ... 06, 2016 , ... Discovering new clues to natural treatments that could allow ... in our brains. And searching for keys to our immune systems by studying parasite-resistant ... the 2017 Edith and Peter O’Donnell Awards by The Academy of ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/28/2016)... , Nov. 28, 2016 ... rate of 16.79%" The biometric system market is ... further in the near future. The biometric system market ... in 2022, at a CAGR of 16.79% between 2016 ... integration of biometric technology in smartphones, rising use of ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):